ConductScience.org, home

Paper40419987

Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.

Lv M and 2 others. BMC Gastroenterol, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis. Papers, record 40419987. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40419987

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.
PubMed
Journal
BMC Gastroenterol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Systematic Review, Meta-Analysis
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-09-24
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lv MMinfang
2Shafagh GGhavam
3Yu SSaiting

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
SynbioticsMajor topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Heart Disease Risk FactorsMajor topic
Cardiovascular DiseasesMajor topic
Humans
Blood Pressure
Lipids
Randomized Controlled Trials as Topic
Waist Circumference

Source PubMed

Download CSV of topics

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128250783Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial.J Res Med Sci2016https://conductscience.org/library/papers/28250783PubMed
232859329The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial.Clin Nutr ESPEN2020https://conductscience.org/library/papers/32859329PubMed
335981707Probiotic therapy, a novel and efficient adjuvant approach to improve glycemic status: An umbrella meta-analysis.Pharmacol Res2022https://conductscience.org/library/papers/35981707PubMed
431009401The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.Eur J Gastroenterol Hepatol2019https://conductscience.org/library/papers/31009401PubMed
529931231Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.J Nutr2018https://conductscience.org/library/papers/29931231PubMed
631547555Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors.Nutrients2019https://conductscience.org/library/papers/31547555PubMed
733259835The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis.Metabolism2021https://conductscience.org/library/papers/33259835PubMed
829584449Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD.Crit Rev Food Sci Nutr2019https://conductscience.org/library/papers/29584449PubMed
934725349Synbiotic (Lactiplantibacillus pentosus GSSK2 and isomalto-oligosaccharides) supplementation modulates pathophysiology and gut dysbiosis in experimental metabolic syndrome.Sci Rep2021https://conductscience.org/library/papers/34725349PubMed
1037111082Effect of a Multispecies Synbiotic Supplementation on Body Composition, Antioxidant Status, and Gut Microbiomes in Overweight and Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study.Nutrients2023https://conductscience.org/library/papers/37111082PubMed
1122190648Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.Diabetes2012https://conductscience.org/library/papers/22190648PubMed
127786990Operating characteristics of a rank correlation test for publication bias.Biometrics1994https://conductscience.org/library/papers/7786990PubMed
1336908920Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Front Nutr2023https://conductscience.org/library/papers/36908920PubMed
1433987427Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.Ann Transl Med2021https://conductscience.org/library/papers/33987427PubMed
1535795187The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/35795187PubMed
1637388120The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis.Ther Adv Gastroenterol2023https://conductscience.org/library/papers/37388120PubMed
1738694388Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials.Ann Med Surg (Lond)2024https://conductscience.org/library/papers/38694388PubMed
1838729941The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.Nutr Diabetes2024https://conductscience.org/library/papers/38729941PubMed
1928345499Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.Br J Nutr2017https://conductscience.org/library/papers/28345499PubMed
2032322969Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials.Eur J Nutr2020https://conductscience.org/library/papers/32322969PubMed

See all 62 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42311765Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Front Cardiovasc Med2026https://conductscience.org/library/papers/42311765PubMed
41902532Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue.Endocrinol Diabetes Metab2026https://conductscience.org/library/papers/41902532PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40419987

GET https://conductscience.org/api/papers/v1/40419987/references?page=2